Complete response plus partial response Length of · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to higher complete response plus partial response Length of compared with TACE alone (low certainty).
1 finding from 1 review
All‐cause mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse events or complications · people with liver metastases
1 finding from 1 review
Disease-free survival · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).
1 finding from 1 review
Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Elevated alanine aminotransferase Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated alanine aminotransferase Length of compared with TACE alone (very low certainty).
1 finding from 1 review
Elevated total bilirubin Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated total bilirubin Length of compared with TACE alone (very low certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review